Author of

• 25938

  +

  P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 26925

    +

    P2.01-120 - First Study to Evaluate the Efficacy of SB Oral Solution to Prevent Neutropenia and FN Induced by Platinum-Based Chemotherapy in Lung Cancer (ID 13272)

    16:45 - 18:00  |  Author(s): Ting Li
    • Abstract

    Background
    

    The aim of this study is to investigate the efficiency of Shengbai Oral Solution to Neutropenia and Febrile Neutropenia induced by platinum-based chemotherapy in lung cancer.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    A total of 295 lung cancer patients from January 2014 through December 2016 were treated with platinum-based chemotherapy including etoposide or paclitaxel liposome combined with cisplatin (75mg/m², one day finished) or carboplatin (AUC=6.25, one day finished), and 91 of them were treated with Shengbai Oral Solution. Using the ratio 1:2 with propensity score matching (PSM), the control group of 169 patients was matched to the experimental group of 91 patients, and the remaining 35 patients were excluded. The primary end point was to evaluate the effectiveness of Shengbai Oral Solution in preventing grade 2/3/4 drug-related toxicities of neutropenia. And the secondary outcome was to evaluate the rate of Febrile Neutropeniathe, cost and toxicity. All the patients were from this clinical trials with the NCT number of NCT01980212.

    4c3880bb027f159e801041b1021e88e8 Result
    

    There were no difference between two groups, with gender, age, smoking status, histologic grade, and histologic type included. The study revealed that compared with the control group, the ratio of neutropenia in the experimental group was significantly lower (34.07% vs 64.50%, HR 0.53, p<0.05), as expected, the grade 2/3/4, 3/4 neutropenia had similar results (30.77% vs 55.62%, HR 0.55, p<0.01), (14.29% vs 23.67%, HR 0.60, p<0.05), respectively. And the secondary endpoint showed that Shengbai Oral Solution can signifcantly reduce the rate of Febrile Neutropenia and did not significantly increase the additional medical expenses. There was no intolerance drug related toxicity.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    This study suggested that Shengbai Oral Solution was effective on reducing neutropenia and Febrile Neutropenia caused by chemotherapy in patients with lung cancer and was worth promoting in clinical.

    6f8b794f3246b0c1e1780bb4d4d5dc53